

RESEARCH MONOGRAPH . COMPOUND PROFILE

Tasimelteon

A synthetic dihydrobenzofuran-cyclopropane melatonin receptor agonist developed at Bristol-Myers Squibb and advanced by Vanda Pharmaceuticals as the first FDA-approved pharmacotherapy for Non-24-Hour Sleep-Wake Disorder in totally blind individuals and for nighttime sleep disturbances in Smith-Magenis Syndrome.

DOCUMENT	KDC-MN-1629
ISSUED	2026-05-21
REVISION	1.0
AUTHOR	Kodiac biolabs Research
COMPOUND CLASS	Dual melatonin receptor agonist (MT1/MT2) with circadian rhythm entrainment activity

ABSTRACT

Tasimelteon (VEC-162, BMS-214778) is an orally active, selective dual agonist of the melatonin MT1 and MT2 G-protein-coupled receptors, approved by the United States Food and Drug Administration for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) in totally blind individuals (January 2014) and for the treatment of nighttime sleep disturbances associated with Smith-Magenis Syndrome (December 2020). The compound is marketed by Vanda Pharmaceuticals under the trade name Hetlioz and was originally synthesized at Bristol-Myers Squibb as BMS-214778 before being licensed to Vanda in 2004 for clinical development. Tasimelteon is a circadian regulator that resets the master body clock in the suprachiasmatic nucleus of the hypothalamus by engaging both melatonin receptor subtypes, with approximately 2.1- to 4.4-fold greater affinity for the MT2 receptor (K_i approximately 0.07 to 0.17 nM) than for the MT1 receptor (K_i approximately 0.30 to 0.35 nM). The compound and its major metabolites have no appreciable affinity for more than 160 other pharmacologically relevant receptors, including gamma-aminobutyric acid, serotonin, noradrenaline, acetylcholine, dopamine, and opiate receptor systems, conferring a remarkably clean selectivity profile among circadian-active agents.

The clinical evidence base for tasimelteon rests principally on two pivotal Phase 3 trials (SET and RESET), published in *The Lancet* in 2015, which demonstrated that 20 mg of oral tasimelteon administered nightly entrained the circadian pacemaker in totally blind individuals with Non-24 and that continued treatment was

necessary to maintain entrainment. In the SET trial, tasimelteon achieved the co-primary endpoints of circadian entrainment of the melatonin rhythm and clinical response compared with placebo. In the RESET withdrawal trial, patients randomized to placebo after an entrainment run-in period showed significant deterioration in nighttime sleep, daytime sleep, and timing of sleep, while patients maintained on tasimelteon preserved their clinical benefit. A supplemental indication for Smith-Magenis Syndrome was approved in December 2020 based on a randomized, double-blind, placebo-controlled crossover study demonstrating improvement in nighttime sleep disturbances in both adults and children with this rare neurodevelopmental disorder characterized by an inverted circadian melatonin rhythm. A supplemental application for jet lag disorder has been twice rejected by the FDA (in 2019 and again in January 2026 upon re-review), despite court-ordered reconsideration by the DC Circuit Court of Appeals.

Pharmacokinetics are characterized by rapid oral absorption (T_{max} 0.5 to 3 hours), moderate oral bioavailability (approximately 38 percent), high plasma protein binding (approximately 90 percent), a short elimination half-life (1.3 hours), and extensive hepatic metabolism primarily through CYP1A2 and CYP3A4 oxidation pathways. The short half-life distinguishes tasimelteon from melatonin itself and from ramelteon and reflects the rapid clearance of the parent compound, with the chronobiotic effect being mediated by the timing of receptor occupancy rather than sustained plasma exposure. Eighty percent of an administered dose is recovered in urine as metabolites, with less than 1 percent excreted as unchanged parent compound. The five most abundant metabolites (M9, M11, M12, M13, M14) retain binding activity at the MT1 and

MT2 receptors but at less than one-tenth the affinity of the parent compound. Clinically significant drug interactions include a 7-fold increase in exposure with fluvoxamine (a strong CYP1A2 inhibitor), a 90 percent decrease in exposure with rifampin (a strong CYP3A4 inducer), and an approximately 40 percent decrease in exposure in tobacco smokers (reflecting CYP1A2 induction). Elderly patients (older than 65 years) exhibit approximately 2-fold higher exposure than younger adults.

This monograph reviews the chemistry, synthesis, and stereochemistry of tasimelteon; the dual melatonin receptor agonist pharmacology and circadian mechanism; the comprehensive human pharmacokinetic record including drug-drug interactions and special populations; the preclinical chronobiology; the clinical evidence base across Non-24, Smith-Magenis Syndrome, jet lag disorder, and insomnia indications; sourcing and quality verification for research applications; reconstitution and handling; stack-interaction considerations; adverse-event signal; and a structured comparative assessment of five melatonin receptor agonists and related circadian agents (ramelteon, prolonged-release melatonin, agomelatine, suvorexant, and melatonin) against tasimelteon on five competency standards (novelty, effect size, promising potential, side-effect profile, and overall validation).

1. Compound Identification

1.1 Names, synonyms, and registry identifiers

International Nonproprietary Name: Tasimelteon.

Marketed name: Hetlio[®] (Vanda Pharmaceuticals; United States, European Union). A liquid oral suspension formulation, Hetlio[®] LQ, is also marketed for pediatric and adult use in Smith-Magenis Syndrome.

Development codes: VEC-162 (Vanda Pharmaceuticals), BMS-214778 (Bristol-Myers Squibb). The BMS designation is the original identifier from the discovery program; VEC-162 is the development code under which the compound advanced through Phase 2 and Phase 3 clinical trials [1, 2].

Chemical Abstracts Service registry number: 609799-22-6 (free base). The free base is the synthetic and formulated form; no separate salt form is registered for pharmaceutical use.

International Union of Pure and Applied Chemistry name: (1R,2R)-N-[2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl propanamide. The compound features a trans-disubstituted cyclopropane ring connecting a 2,3-dihydrobenzofuran heterocycle to a propanamide side chain.

1.2 Structural class and chemistry

Tasimelteon is a synthetic melatonin receptor agonist of the dihydrobenzofuran-cyclopropane structural class. The compound is structurally related to melatonin (N-acetyl-5-methoxytryptamine) at the pharmacophore level but replaces the indole nucleus with a dihydrobenzofuran ring system and replaces the flexible ethylamine linker with a conformationally constrained trans-cyclopropane, conferring improved receptor selectivity and metabolic stability relative to melatonin itself [3, 4].

Molecular formula: C₁₅H₁₉NO₂.

Molecular weight: 245.32 g/mol (monoisotopic mass 245.1416).

Physical properties: White to off-white crystalline solid. Slightly soluble in water. Soluble in dimethyl sulfoxide, methanol, and ethanol. The compound is supplied as a crystalline powder for research applications and as a gelatin capsule containing 20 mg of tasimelteon for the marketed pharmaceutical formulation.

Stereochemistry: Tasimelteon contains two stereocenters at the 1- and 2-positions of the cyclopropane ring and is supplied as the single (1R,2R)-trans enantiomer. The trans-cyclopropane geometry constrains the spatial relationship between the dihydrobenzofuran ring and the propanamide side chain, and this geometry is essential for high-affinity binding to the MT1 and MT2 melatonin receptors. Investigators acquiring research-grade tasimelteon should confirm enantiomeric purity by chiral high-performance liquid chromatography.

1.3 Synthesis

The published synthesis of tasimelteon proceeds through construction of the trans-disubstituted cyclopropane core, typically via a Simmons-Smith cyclopropanation or a transition-metal-catalyzed carbene insertion onto a 2,3-dihydrobenzofuran-4-yl vinyl precursor [5]. The key synthetic challenge is the stereoselective generation of the (1R,2R)-trans-cyclopropane with high enantiomeric excess. The cyclopropane carboxaldehyde intermediate is converted to the primary amine through reductive amination or through a Curtius or Hofmann rearrangement sequence, and the propanamide is installed by acylation of the primary amine with propionic anhydride or propionyl chloride. Industrial syntheses optimize the cyclopropanation step for stereochemical control (greater than 99 percent enantiomeric excess) and the acylation step for yield and purity. The compound is purified by recrystallization or chromatography and characterized by nuclear magnetic resonance spectroscopy, mass spectrometry, high-performance liquid chromatography, and chiral chromatography.

2. Abstract

Tasimelteon (VEC-162, BMS-214778) is a potent, selective dual agonist of the melatonin MT1 and MT2 receptors and the first pharmacotherapy approved by the United States Food and Drug Administration for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) in totally blind individuals who lack light perception [1, 2]. The compound was subsequently approved in December 2020 for the treatment of nighttime sleep disturbances associated with Smith-Magenis Syndrome (SMS), a rare neurodevelopmental disorder characterized by an inverted circadian melatonin rhythm [6]. Tasimelteon is marketed by Vanda Pharmaceuticals as Hetlioz at a dose of 20 mg orally once nightly, one hour before bedtime.

The pharmacological mechanism is circadian entrainment through activation of MT1 and MT2 receptors in the suprachiasmatic nucleus (SCN) of the hypothalamus, the master circadian pacemaker. In totally blind individuals who lack the photic zeitgeber (light input through the retinohypothalamic tract), the circadian clock free-runs with an intrinsic period slightly longer than 24 hours, producing the cyclical misalignment of sleep, wake, hormonal, and behavioral rhythms that constitutes Non-24 [7, 8]. Tasimelteon provides a daily pharmacological time cue that substitutes for the absent photic signal, entraining the circadian clock to a 24-hour period and restoring alignment between the endogenous clock and the desired sleep-wake schedule.

Receptor binding studies demonstrate K_i values of 0.30 to 0.35 nM at the MT1 receptor and 0.07 to 0.17 nM at the MT2 receptor, corresponding to a 2.1- to 4.4-fold selectivity for MT2 [9]. Both receptors are G_i/G_o -coupled G-protein-coupled receptors that inhibit adenylyl cyclase and reduce intracellular cyclic adenosine monophosphate upon activation. Tasimelteon functions as a full agonist at both receptor subtypes in functional cAMP inhibition assays. The compound and its major metabolites have no appreciable affinity for more than 160 other pharmacologically relevant receptors and enzymes, including GABA, serotonin, noradrenaline, acetylcholine, dopamine, histamine, and opiate receptors [9, 10].

Pharmacokinetics are characterized by rapid oral absorption, moderate bioavailability (38 percent), high plasma protein binding (90 percent), a short elimination half-life (1.3 hours), and extensive hepatic metabolism through CYP1A2 and

CYP3A4 [11, 12]. The clinical evidence base comprises two pivotal Phase 3 trials (SET and RESET) in Non-24, a crossover study in Smith-Magenis Syndrome, Phase 3 data in transient insomnia, and a jet lag simulation model [2, 6, 13, 14]. The compound is well tolerated; the principal adverse events are headache (17 percent), alanine aminotransferase elevation (10 percent), nightmares or unusual dreams (10 percent), and upper respiratory or urinary tract infections (7 percent) [15].

3. Discovery and Development History

3.1 Origin

Tasimelteon was synthesized at Bristol-Myers Squibb as part of a melatonin receptor agonist medicinal chemistry program in the late 1990s, under the internal designation BMS-214778 [3]. The program sought to identify conformationally constrained analogs of melatonin with improved receptor selectivity, metabolic stability, and pharmacokinetic properties relative to the endogenous ligand. Tasimelteon emerged from a structure-activity relationship series in which the flexible ethylamine linker of melatonin was replaced with a trans-cyclopropane, and the indole nucleus was replaced with a dihydrobenzofuran, yielding a compound with subnanomolar affinity for both MT1 and MT2 receptors and a clean off-target selectivity profile. Bristol-Myers Squibb advanced the compound through initial preclinical pharmacology and toxicology studies.

3.2 License to Vanda Pharmaceuticals

In 2004, Vanda Pharmaceuticals, Inc. (Rockville, Maryland) obtained an exclusive license to tasimelteon (redesignated VEC-162) from Bristol-Myers Squibb [1]. Vanda's development strategy focused on circadian rhythm sleep-wake disorders rather than on the broader insomnia market, reflecting the compound's mechanism of action as a circadian entrainment agent rather than a sedative-hypnotic. This strategic positioning distinguished the tasimelteon development program from the ramelteon (Rozerem) program at Takeda, which had advanced on an insomnia indication and received FDA approval in 2005.

3.3 Phase 2 development in transient insomnia

Vanda conducted Phase 2 studies of tasimelteon in the induced insomnia (5-hour phase advance) model in healthy volunteers, demonstrating dose-dependent reductions in sleep latency and improvements in sleep efficiency at doses of 10 to 100 mg [13]. These studies established the pharmacodynamic proof of concept for the chronobiotic mechanism and informed the dose selection for subsequent circadian rhythm disorder trials.

3.4 Phase 3 development in transient insomnia

In June 2008, Vanda reported positive Phase 3 results for tasimelteon in patients with chronic insomnia, demonstrating that the compound significantly improved sleep latency and sleep maintenance [14]. However, Vanda elected not to pursue the insomnia indication for initial registration, instead prioritizing the orphan Non-24 indication in totally blind individuals, where the unmet medical need was greater, the regulatory pathway was more defined, and the mechanism of action (circadian entrainment) was most directly aligned with the compound's pharmacology.

3.5 Registration for Non-24-Hour Sleep-Wake Disorder

Vanda submitted a New Drug Application for tasimelteon in Non-24 based on the pivotal SET and RESET Phase 3 trials. The FDA approved Hetlioz on January 31, 2014, making it the first (and, as of the most recent monograph revision, the only) pharmacotherapy approved for Non-24 [2, 15]. The European Medicines Agency subsequently granted marketing authorization for the same indication.

3.6 Supplemental approval for Smith-Magenis Syndrome

In December 2020, the FDA approved a supplemental application for Hetlioz (capsule) and Hetlioz LQ (oral suspension) for the treatment of nighttime sleep disturbances in adults and children with Smith-Magenis Syndrome [6]. SMS is a rare neurodevelopmental disorder caused by deletions or mutations in the RAI1 gene on chromosome 17p11.2, and its cardinal features include intellectual disability, behavioral disturbances, and a characteristic inversion of the circadian melatonin rhythm in which melatonin secretion peaks during the daytime and is absent or markedly reduced at night. The approval was based on a randomized, double-blind, placebo-controlled, two-period crossover study.

3.7 Jet lag disorder and insomnia sNDA

Vanda submitted a supplemental New Drug Application (sNDA) for jet lag disorder in October 2018. The FDA issued a Complete Response Letter in 2019, citing insufficient clinical significance of the efficacy measures [16]. Vanda pursued a legal challenge; in 2024, the US Court of Appeals for the DC Circuit ordered the FDA to reconsider its rejection, ruling that Vanda had provided meaningful evidence of efficacy. Upon re-review, the FDA again concluded in January 2026 that the sNDA could not

be approved in its current form [17]. A separate sNDA for insomnia was also rejected by the FDA, which cited concerns about the generalizability of study models to real-world conditions. The compound therefore remains approved for two indications: Non-24 and SMS-associated sleep disturbances.

4. Mechanism of Action

Tasimelteon is a selective dual melatonin receptor agonist. Its molecular mechanism is the activation of MT1 and MT2 G-protein-coupled receptors in the suprachiasmatic nucleus and other melatonin-responsive tissues, producing circadian phase-shifting and entrainment effects that constitute the therapeutic basis for the approved indications.

4.1 MT1 and MT2 melatonin receptors

The melatonin receptors MT1 (MTNR1A) and MT2 (MTNR1B) are class A (rhodopsin-like) G-protein-coupled receptors that couple primarily to inhibitory G-proteins (Gi/Go). Upon activation, both receptors inhibit adenylyl cyclase, reducing intracellular cyclic adenosine monophosphate (cAMP) and activating downstream signaling cascades including protein kinase C, mitogen-activated protein kinase pathways, and ion channel modulation [18, 19].

MT1 receptors are expressed at high density in the suprachiasmatic nucleus, the pars tuberalis of the pituitary, the retina, and at lower density throughout the central nervous system and in peripheral tissues including cardiovascular, immune, and reproductive systems. Activation of MT1 receptors in the SCN acutely inhibits neuronal firing, contributing to the sleep-promoting and circadian phase-maintaining functions of endogenous melatonin [18].

MT2 receptors are expressed in the SCN, the retina, the hippocampus, and in peripheral tissues including bone and immune cells. MT2 activation in the SCN mediates circadian phase-shifting, the principal chronobiotic action through which melatonin (and melatonin agonists) reset the timing of the circadian clock [19]. The MT2 receptor is therefore considered the primary pharmacological target for circadian entrainment applications.

4.2 Receptor binding and functional activity of tasimelteon

Tasimelteon binds the human MT1 receptor with K_i values of 0.304 to 0.35 nM and the human MT2 receptor with K_i values of 0.0692 to 0.17 nM, as determined in radioligand displacement assays in NIH-3T3 and CHO-K1 cell lines expressing the re-

combinant human receptors [9]. The 2.1- to 4.4-fold preferential affinity for MT2 over MT1 is consistent with a chronobiotic pharmacological profile in which circadian phase-shifting (MT2-dependent) is favored over acute sleep promotion (MT1-dependent).

In functional assays, tasimelteon acts as a full agonist at both MT1 and MT2 receptors, effectively inhibiting forskolin-stimulated cAMP production with potency comparable to melatonin [9, 10]. The compound does not exhibit partial agonism or inverse agonism at either receptor subtype at any tested concentration.

4.3 Selectivity

Tasimelteon and its five major metabolites (M9, M11, M12, M13, M14) were screened against a panel of more than 160 pharmacologically relevant receptors, ion channels, transporters, and enzymes. No appreciable binding affinity (K_i greater than 1 micromolar) was detected at any non-melatonin target, including GABA-A, GABA-B, serotonin (5-HT1A, 5-HT2A, 5-HT2C, 5-HT3), dopamine (D1 through D5), noradrenaline (alpha-1, alpha-2, beta), histamine (H1, H2, H3), acetylcholine (muscarinic M1 through M5, nicotinic), opiate (mu, delta, kappa), benzodiazepine, and cannabinoid (CB1, CB2) receptors [9, 10]. This selectivity profile is the cleanest among the marketed melatonin receptor agonists and distinguishes tasimelteon from agomelatine, which has additional 5-HT2C antagonist activity.

4.4 Circadian entrainment mechanism

The therapeutic mechanism of tasimelteon in Non-24 is circadian entrainment: the synchronization of the endogenous circadian clock to a 24-hour period through daily pharmacological activation of MT1 and MT2 receptors in the SCN at a fixed clock time [7, 8]. In sighted individuals, the principal zeitgeber is light acting through melanopsin-containing intrinsically photosensitive retinal ganglion cells that project to the SCN via the retinohypothalamic tract. In totally blind individuals who lack light perception, this photic input is absent, and the circadian clock free-runs with an intrinsic period (τ) of approximately 24.2 to 24.5 hours [7]. The progressive daily drift of the circadian clock relative to the 24-hour social day produces cyclical periods of alignment and misalignment, manifesting as the sleep-wake disruption, daytime somnolence, and nighttime insomnia that constitute Non-24.

Tasimelteon, administered at a fixed clock time nightly, provides a daily pharmacological phase-advance signal that counteracts the intrinsic period longer than 24 hours and entrains the clock to a 24-hour period. The entrainment is assessed by measurement of the circadian melatonin and cortisol rhythms (6-sulphatoxymelatonin in urine, cortisol acrophase) and by clinical measures of sleep timing and quality [2].

4.5 Smith-Magenis Syndrome mechanism

In Smith-Magenis Syndrome, the circadian melatonin rhythm is characteristically inverted, with melatonin secretion peaking during daytime hours rather than at night [6]. This inversion is attributed to dysregulation of the RAI1-dependent molecular clock machinery. Tasimelteon provides an exogenous melatonergic signal at the appropriate circadian phase (bedtime), partially compensating for the absent or mistimed endogenous melatonin signal and improving nighttime sleep consolidation.

5. Pharmacokinetics and Routes of Administration

5.1 Absorption

Tasimelteon is rapidly absorbed from the gastrointestinal tract after oral administration. The time to peak plasma concentration (T_{max}) ranges from 0.5 to 3 hours in fasted healthy subjects [11, 12]. Absolute oral bioavailability, determined in a crossover study of oral versus intravenous administration in 14 healthy volunteers, is 38.3 percent [20]. The moderate bioavailability reflects substantial first-pass hepatic metabolism. Food has a clinically significant effect on absorption: a high-fat meal reduces C_{max} by 44 percent and delays T_{max}; therefore, the prescribing information recommends administration without food [15].

5.2 Distribution

Tasimelteon is approximately 90 percent bound to plasma proteins. The volume of distribution has not been published in detail but is consistent with moderate tissue distribution. The compound crosses the blood-brain barrier, as required by its mechanism of action at the suprachiasmatic nucleus [11].

5.3 Metabolism

Tasimelteon is extensively metabolized in the liver, primarily by oxidation at multiple sites. The principal cytochrome P450 isoforms responsible for metabolism are CYP1A2 (contributing approximately 35 percent of total clearance) and CYP3A4/5 (approximately 24 percent), with secondary contributions from CYP2C9 (approximately 19 percent) and CYP2C19 (approximately 15 percent) [11, 12, 21].

The metabolic pathways include oxidation at multiple positions on the dihydrobenzofuran ring and the propanamide side chain, oxidative dealkylation resulting in opening of the dihydrofuran ring followed by further oxidation to a carboxylic acid, and phenolic glucuronidation as the major Phase II conjugation route. Five major metabolites have been characterized (designated M9, M11, M12, M13, and M14). All five retain binding activity at the MT1 and MT2 receptors but with

less than one-tenth the affinity of the parent compound; the metabolites are therefore not expected to contribute materially to the chronobiotic effect at clinical exposure levels [9, 15].

5.4 Elimination

The observed mean elimination half-life of tasimelteon is 1.3 plus or minus 0.4 hours [11, 15]. The main metabolites have terminal elimination half-lives ranging from 1.3 to 3.7 hours. Following oral administration of radiolabeled tasimelteon, 80 percent of total radioactivity was recovered in urine and approximately 4 percent in feces, with less than 1 percent of the administered dose excreted as unchanged parent compound in urine [15]. Elimination is therefore predominantly metabolic (hepatic biotransformation) rather than renal.

5.5 Routes of administration

The approved route of administration is oral. Tasimelteon is supplied as a 20 mg gelatin capsule (Hetlioz) and as an oral suspension (Hetlioz LQ) for patients who cannot swallow capsules, including pediatric patients with Smith-Magenis Syndrome. The capsule and suspension formulations are not interchangeable on a milligram-per-milligram basis [15]. The recommended dose for both approved indications is 20 mg administered one hour before bedtime at the same time each night.

5.6 Special populations

Elderly patients: Exposure to tasimelteon in patients older than 65 years is approximately 2-fold higher than in younger adults, reflecting age-related reductions in hepatic metabolic capacity [15]. No dose adjustment is specified in the prescribing information, but the increased exposure should be considered in adverse-event interpretation.

Hepatic impairment: In subjects with mild or moderate hepatic impairment, exposure after a single 20 mg dose was increased approximately 2-fold [12]. No dose adjustment is recommended for mild or moderate impairment. Tasimelteon has not been studied in severe hepatic impairment and is not recommended for use in that population.

Renal impairment: No apparent relationship between tasimelteon clearance and renal function was identified [12]. No dose adjustment is required in renal impairment.

Smokers: Tobacco smoking (a moderate CYP1A2 inducer) reduces tasimelteon exposure by approximately 40 percent [15, 21]. An increase in tasimelteon dose may be needed in current smokers to achieve equivalent circadian effects.

Pediatric patients: Tasimelteon is approved for use in pediatric patients with Smith-Magenis Syndrome (Hetlioz LQ oral suspension). Dosing in the SMS indication is weight-based for pediatric patients.

6. Preclinical Pharmacology

6.1 In vitro receptor pharmacology

The receptor binding profile of tasimelteon was characterized in radioligand displacement assays using 2-[125I]-iodomelatonin at recombinant human MT1 and MT2 receptors expressed in NIH-3T3 and CHO-K1 cells [9]. Ki values at MT2 were 0.0692 nM (NIH-3T3) and 0.17 nM (CHO-K1); Ki values at MT1 were 0.304 nM (NIH-3T3) and 0.35 nM (CHO-K1). The selectivity ratio (MT1 Ki / MT2 Ki) was 2.1 to 4.4, consistent with preferential MT2 engagement.

Functional agonism was confirmed in cAMP inhibition assays: tasimelteon fully inhibited forskolin-stimulated cAMP production through both Gi-coupled receptor subtypes, with potency comparable to melatonin [9, 10]. No partial agonist, antagonist, or inverse agonist activity was detected at any tested concentration.

The broad selectivity screen (more than 160 targets) confirmed the absence of appreciable off-target activity, supporting the clean adverse-event profile observed in clinical trials [9].

6.2 Circadian pharmacology in animal models

In rodent circadian models, tasimelteon produced dose-dependent phase shifts of circadian activity rhythms at doses of 1 to 5 mg/kg (corresponding to human-equivalent doses of approximately 10 to 50 mg) [3, 22]. In free-running activity models (animals maintained in constant darkness to allow the endogenous circadian clock to free-run), tasimelteon entrained the activity cycle to a 24-hour period when administered daily at a fixed circadian time, confirming the chronobiotic mechanism.

The phase-shifting potency of tasimelteon in animal models was comparable to melatonin but with a longer duration of action attributable to improved metabolic stability of the dihydrobenzofuran-cyclopropane scaffold relative to the rapidly cleared indole nucleus of melatonin [3].

6.3 Sleep pharmacology

In preclinical sleep studies, tasimelteon promoted sleep onset without producing the residual next-day sedation characteristic of GABA-A receptor modulators (benzodiazepines, non-benzodiazepine hypnotics) [22]. This absence of residual sedation is consistent with the non-GABAergic, melatonergic mechanism and distinguishes the compound from the sedative-hypnotic class.

6.4 Safety pharmacology

Preclinical safety pharmacology studies demonstrated no significant effects on cardiovascular parameters (heart rate, blood pressure, QT interval), respiratory function, or central nervous system function at multiples of the clinical dose. The compound did not demonstrate abuse potential, physical dependence, or withdrawal effects in animal models, consistent with the non-GABAergic, non-opioidergic mechanism [15].

7. Clinical Evidence Base

7.1 Non-24-Hour Sleep-Wake Disorder: SET and RESET trials

The pivotal clinical evidence for the Non-24 indication comprises two Phase 3 trials published together by Lockley et al. in The Lancet in 2015 [2].

SET trial (Safety and Efficacy of Tasimelteon): A multicenter, randomized, double-masked, placebo-controlled trial in totally blind individuals with Non-24. Patients received 20 mg of tasimelteon or placebo nightly for approximately 6 months. The co-primary endpoints were (1) entrainment of the circadian melatonin rhythm, assessed by the urinary 6-sulphatoxymelatonin (aMT6s) timing, and (2) clinical response, assessed by improvement in Clinical Global Impression of Change scores and reductions in nighttime and daytime sleep complaints. Tasimelteon achieved both co-primary endpoints compared with placebo: a significantly greater proportion of tasimelteon-treated patients demonstrated entrainment of the melatonin rhythm, and clinical response rates were significantly higher in the tasimelteon group [2].

RESET trial (Randomized withdrawal of Entrainment after Successful Entrainment with Tasimelteon): A randomized withdrawal trial in which patients who had achieved circadian entrainment on tasimelteon during an open-label run-in phase were randomized to continue tasimelteon or switch to placebo. The primary endpoint was maintenance of entrainment. Patients randomized to placebo showed statistically significant deterioration in circadian melatonin and cortisol rhythms, nighttime sleep, daytime sleep, and timing of sleep, while patients maintained on tasimelteon preserved their clinical benefit [2]. This withdrawal design demonstrated that continued tasimelteon treatment is necessary to sustain entrainment in the absence of photic zeitgebers.

7.2 Smith-Magenis Syndrome

The SMS indication was supported by a randomized, double-blind, placebo-controlled, two-period crossover study in adults and children with Smith-Magenis Syndrome [6]. Patients received tasimelteon or placebo for defined treatment peri-

ods, and the primary endpoint was improvement in nighttime sleep as measured by actigraphy and clinical assessment. Tasimelteon demonstrated statistically significant improvement in nighttime total sleep time and other sleep parameters compared with placebo. The study was published by De Leersnyder et al. and supported the December 2020 FDA approval of both Hetlioz capsules (adults) and Hetlioz LQ oral suspension (pediatric patients) [6, 23].

7.3 Transient insomnia and Phase 3 insomnia data

Vanda conducted Phase 2 and Phase 3 studies of tasimelteon in transient and chronic insomnia models [13, 14]. In the 5-hour phase advance model of transient insomnia in healthy volunteers, tasimelteon at doses of 20 to 100 mg reduced sleep latency and improved sleep efficiency compared with placebo [13]. In the Phase 3 chronic insomnia trial reported in June 2008, tasimelteon met the primary endpoint of significant improvement in sleep latency [14]. However, Vanda did not pursue the insomnia indication for regulatory approval, prioritizing the Non-24 orphan indication. A subsequent sNDA for insomnia was rejected by the FDA.

7.4 Jet lag disorder

Vanda conducted clinical studies using a jet lag simulation model and submitted an sNDA for jet lag disorder in October 2018 [16]. The studies demonstrated statistically significant improvement on primary sleep endpoints in the simulation model. The FDA issued a Complete Response Letter in 2019, stating that the measures demonstrating improved sleep were of unclear clinical significance and questioning the translatability of the simulation model to real-world jet travel conditions. Following a DC Circuit Court ruling ordering reconsideration, the FDA re-reviewed the application and again concluded in January 2026 that the sNDA could not be approved in its current form [17]. Tasimelteon is therefore not approved for jet lag disorder despite positive efficacy signals in the simulation studies.

7.5 Autism spectrum disorder and sleep disturbances

A Phase 3 clinical trial (NCT number registered on ClinicalTrials.gov) has investigated tasimelteon for sleep-wake disturbances associated with autism spectrum disorder [24]. This study reflects the broader investigational interest in melatonin

receptor agonists for circadian and sleep dysregulation in neurodevelopmental conditions. Results have not been published in a peer-reviewed forum as of the most recent monograph revision.

8. Sourcing and Quality Verification

Pharmaceutical-grade tasimelteon is available as the marketed formulation Hetlio[®]z (20 mg capsules, Vanda Pharmaceuticals) and Hetlio[®]z LQ (oral suspension) through licensed pharmacies in the United States and in jurisdictions where marketing authorization has been granted. The pharmaceutical-grade material is the highest-quality source for clinical research applications.

Research-grade tasimelteon is supplied by multiple chemical and pharmaceutical research suppliers (Sigma-Aldrich/MilliporeSigma [catalog SML2030], Selleck Chemicals, MedChemExpress, Tocris, Cayman Chemical, AbMole BioScience, GlpBio, BocSci, Chem-Impex, and others) at greater than 98 percent purity by high-performance liquid chromatography [25, 26]. Supply is in milligram to gram quantities as the free base. Pricing is moderate for a small-molecule research compound.

Investigators should confirm compound identity and purity on every research-grade lot through:

- High-performance liquid chromatography area-percent purity, ideally greater than 98 percent
- Mass spectrometry confirmation of molecular weight (246.15 for the protonated species $[M+H]^+$, exact mass 245.1416 for the free base)
- Chiral high-performance liquid chromatography confirmation of enantiomeric purity (greater than 99 percent enantiomeric excess of the (1R,2R)-trans form)
- Nuclear magnetic resonance spectroscopy (1H and ^{13}C) for structural confirmation
- Karl Fischer or loss-on-drying analysis for residual water content
- Residual solvent analysis by gas chromatography

Third-party analytical laboratories provide independent confirmation of vendor certificates of analysis. The research-grade tasimelteon market is established and the compound is available from reputable suppliers; lot-to-lot variability can occur and on-receipt analytical confirmation is appropriate for investigations where dose-response precision is important.

9. Reconstitution and Handling

Tasimelteon free base is slightly soluble in water but readily soluble in dimethyl sulfoxide (DMSO), methanol, and ethanol. For in vitro research applications, stock solutions are typically prepared at 10 to 50 mM in DMSO and diluted into aqueous assay media to the desired working concentration. Final DMSO concentration in cell-based assays should be kept below 0.1 to 0.5 percent (volume/volume) to avoid solvent toxicity artifacts.

For in vivo research applications, tasimelteon can be formulated in aqueous vehicles using standard pharmaceutical excipients (methylcellulose, carboxymethylcellulose, Tween 80) or in PEG-based formulations. The marketed oral capsule formulation uses standard pharmaceutical excipients for the gelatin capsule shell and fill.

Storage conditions: Research-grade tasimelteon powder should be stored at minus 20 degrees Celsius in a desiccated, light-protected container. The compound is stable under these conditions for at least 24 months from the date of manufacture (consult supplier certificate of analysis for lot-specific stability data). DMSO stock solutions should be stored in aliquots at minus 20 degrees Celsius to avoid repeated freeze-thaw cycles; stability of DMSO stocks has been demonstrated for at least 3 months under these conditions.

Light sensitivity: Tasimelteon is not reported as highly photolabile, but standard practice for melatonin-class compounds is to minimize prolonged exposure to direct light during handling and storage.

Handling precautions: Standard laboratory personal protective equipment (gloves, safety glasses, laboratory coat) is appropriate. The compound is not classified as acutely hazardous, but should be handled with the precautions appropriate for any pharmacologically active research compound.

10. Stack Interactions and Combinations

Tasimelteon interacts with several drug classes through its CYP1A2- and CYP3A4-dependent metabolism and through its melatonergic pharmacology. Investigators conducting research with tasimelteon, particularly in chronic dosing regimens or in combination with other compounds, should consider the following interactions:

Strong CYP1A2 inhibitors: Fluvoxamine (50 mg daily for 6 days) increased tasimelteon AUC 7-fold and C_{max} 2-fold [15, 21]. This interaction is the most clinically significant drug-drug interaction for tasimelteon. Other strong CYP1A2 inhibitors (ciprofloxacin, enoxacin) are expected to produce similar magnitude increases. Combination with strong CYP1A2 inhibitors should be avoided because of the potentially large increase in tasimelteon exposure and greater risk of adverse reactions.

Strong CYP3A4 inducers: Rifampin (a potent CYP3A4 inducer and moderate CYP1A2 inducer) decreased tasimelteon exposure by approximately 90 percent [15]. Other strong CYP3A4 inducers (phenytoin, carbamazepine, St. John's wort) are expected to produce substantial reductions in exposure. Concurrent use with strong CYP3A4 inducers should be avoided because of the potentially large decrease in tasimelteon exposure and reduced efficacy.

Tobacco smoking: Smoking is a moderate CYP1A2 inducer and reduces tasimelteon exposure by approximately 40 percent [15]. Efficacy may be reduced in smokers; dose adjustment may be necessary.

Beta-adrenergic blockers: The prescribing information notes that beta-blockers may reduce the efficacy of tasimelteon [15]. The mechanism is likely related to the suppression of endogenous melatonin secretion by beta-blockers (melatonin synthesis in the pineal gland is driven by nocturnal noradrenergic stimulation via beta-1 receptors). The clinical significance of this interaction in patients receiving exogenous melatonin receptor agonism has not been fully characterized.

Other melatonin receptor agonists: Concurrent administration with ramelteon, prolonged-release melatonin, or exogenous melatonin supplements produces additive melatonin receptor activation. The combination is pharmacologically redundant and has not been studied; co-administration is not recommended.

Alcohol: A trend toward additive psychomotor impairment was observed when tasimelteon was co-administered with alcohol [15]. Patients should avoid alcohol use near the time of tasimelteon dosing.

Sedative-hypnotics and CNS depressants: Concurrent use with benzodiazepines, non-benzodiazepine hypnotics (zolpidem, zaleplon, eszopiclone), orexin receptor antagonists (suvorexant, lemborexant), opioids, or sedating antihistamines may produce additive somnolence. The tasimelteon mechanism is non-GABAergic and non-opioidergic, so pharmacodynamic interactions at the receptor level are not expected, but clinical additive sedation should be anticipated.

Moderate CYP1A2 inhibitors: Oral contraceptives (moderate CYP1A2 inhibitors) and other moderate CYP1A2 inhibitors may increase tasimelteon exposure to a lesser extent than fluvoxamine; the clinical significance has not been specifically studied but should be considered [21].

11. Adverse Events and Safety

11.1 Common adverse events

The adverse-event profile of tasimelteon was characterized in placebo-controlled clinical trials and in open-label extension studies [2, 6, 15]. In the pivotal SET trial (N=42 tasimelteon, N=42 placebo), the most common adverse events occurring at greater than 5 percent incidence and at least twice the placebo rate were:

- Headache: 17 percent (tasimelteon) versus 7 percent (placebo)
- Alanine aminotransferase (ALT) elevation: 10 percent versus 5 percent
- Nightmares or abnormal dreams: 10 percent versus 0 percent
- Upper respiratory tract infection: 7 percent versus 0 percent
- Urinary tract infection: 7 percent versus 2 percent

Discontinuation due to adverse events occurred in 6 percent of tasimelteon-treated patients versus 4 percent of placebo-treated patients [15].

11.2 Hepatic safety

In a combined analysis of 6 clinical trials involving tasimelteon given for an average of 1 year, ALT elevations above 3 times the upper limit of normal arose in 6.5 percent of tasimelteon-treated subjects [27]. No elevations exceeded 10 times the upper limit of normal, and none were associated with symptoms, jaundice, or clinically apparent liver injury. Serum enzyme elevations occurred in up to 10 percent of tasimelteon-treated patients compared with 5 percent of placebo controls. The hepatic safety profile is therefore characterized by a modest rate of transaminase elevation without evidence of clinically significant hepatotoxicity. Periodic monitoring of liver function tests may be appropriate in long-term use.

11.3 Somnolence and psychomotor impairment

Tasimelteon can impair the performance of activities requiring complete mental alertness [15]. Patients should limit activity to preparing for bed after taking the dose. The somnolence is consistent with the melatonergic mechanism and the tim-

ing of administration (one hour before bedtime) and is not associated with the residual next-day impairment characteristic of longer-acting GABAergic hypnotics.

11.4 Abuse potential and dependence

Tasimelteon is not a scheduled substance and has not demonstrated abuse potential, physical dependence, or withdrawal effects in preclinical or clinical studies [15]. This profile is consistent with the non-GABAergic, non-opioidergic mechanism and distinguishes tasimelteon from benzodiazepine and non-benzodiazepine hypnotics.

11.5 Reproductive safety

Animal reproductive toxicology studies at multiples of the human dose did not demonstrate teratogenicity. Human pregnancy data are limited; the compound is classified in the pregnancy and lactation labeling format (not the legacy FDA category system). Use in pregnancy should be considered only when the potential benefit justifies the potential risk. Lactation data are limited; it is not known whether tasimelteon is excreted in human milk [15].

11.6 Elderly patients

The risk of adverse reactions may be greater in patients older than 65 years because of the approximately 2-fold increase in tasimelteon exposure in this population [15]. Clinical monitoring in elderly patients is appropriate.

12. Comparable Compounds Assessment

This section presents a structured comparative assessment of five melatonin receptor agonists and circadian-active agents against tasimelteon, evaluated on five competency standards: novelty, effect size, promising potential (current clinical state and trajectory), side-effect profile, and overall validation. The five comparators were selected as the principal melatonin receptor agonists or circadian-mechanism agents with substantive clinical or research evidence in circadian rhythm sleep-wake disorders, with priority given to compounds with FDA or EMA approval or advanced clinical development.

12.1 Ramelteon (Rozerem)

Mechanism: Selective MT1/MT2 melatonin receptor agonist. Binding affinity at MT1 is approximately 6-fold higher than at MT2, the opposite selectivity profile from tasimelteon. Ramelteon is a full agonist at both receptor subtypes [28].

Development trajectory: Developed by Takeda Pharmaceutical Company and approved by the FDA in 2005 for the treatment of insomnia characterized by difficulty with sleep onset [28]. Ramelteon is the first melatonin receptor agonist approved in the United States and has been available for nearly two decades. It is not approved for circadian rhythm sleep-wake disorders.

Novelty: Low. As the first-in-class melatonin receptor agonist to achieve FDA approval, ramelteon established the therapeutic concept but is no longer novel. The mechanism is conventional MT1/MT2 agonism without differentiation.

Effect size: Moderate for sleep onset insomnia. Meta-analyses report reductions in sleep onset latency of approximately 9 to 16 minutes compared with placebo, a statistically significant but clinically modest effect [29]. Ramelteon has not demonstrated efficacy for circadian entrainment in Non-24 or for the maintenance of entrainment; it is not approved for any circadian rhythm sleep-wake disorder.

Promising potential: Low for circadian applications. The compound is established for insomnia but has not expanded to circadian rhythm indications. The MT1-preferring selectivity profile is less favorable for circadian phase-shifting than the MT2-preferring profile of tasimelteon.

Side-effect profile: Favorable. The most common adverse events are somnolence, dizziness, and fatigue. No abuse potential, no scheduled substance classification. Rare reports of decreased testosterone and increased prolactin levels in chronic use [28]. The hepatic safety profile is clean, with no significant transaminase elevation signal.

Overall validation: Moderate to high for insomnia; low for circadian rhythm disorders. Ramelteon has extensive clinical use and a well-characterized safety profile but lacks the circadian entrainment indication.

Comparison to tasimelteon: Ramelteon and tasimelteon share the melatonin receptor agonist mechanism but differ in receptor selectivity (MT1-preferring versus MT2-preferring), approved indication (insomnia versus Non-24/SMS), and clinical evidence for circadian entrainment (absent versus demonstrated). Tasimelteon is the superior choice for circadian rhythm applications; ramelteon is the established choice for sleep onset insomnia. A distinctive pharmacokinetic feature of ramelteon is that its primary metabolite (M-II) is active and achieves 20- to 100-fold higher systemic exposure than the parent compound, a property not shared by tasimelteon metabolites [30].

12.2 Prolonged-release melatonin (Circadin)

Mechanism: Exogenous melatonin in a prolonged-release oral formulation (2 mg). Non-selective MT1/MT2 agonist with the endogenous ligand. Marketed by Neurim Pharmaceuticals [31].

Development trajectory: Approved by the European Medicines Agency in 2007 for the treatment of primary insomnia in patients aged 55 years and older. Not approved by the FDA. Clinical development for circadian rhythm sleep-wake disorders has been limited.

Novelty: Low. The active ingredient is the endogenous ligand; novelty resides only in the prolonged-release formulation.

Effect size: Modest. Meta-analyses report small reductions in sleep onset latency and improvements in subjective sleep quality in adults over 55 [31]. No clinical evidence of circadian entrainment in Non-24 comparable to that demonstrated by tasimelteon.

Promising potential: Low for circadian applications. The compound is established for geriatric insomnia in Europe but has limited trajectory in circadian rhythm indications.

Side-effect profile: Excellent. The endogenous ligand has a very favorable safety profile with minimal adverse events at therapeutic doses. No abuse potential. No significant hepatic safety signal [31].

Overall validation: Moderate for geriatric insomnia; low for circadian rhythm disorders.

Comparison to tasimelteon: Prolonged-release melatonin is the endogenous ligand in a formulated delivery system; tasimelteon is a synthetic agonist with superior metabolic stability and receptor selectivity. Tasimelteon has demonstrated circadian entrainment in clinical trials; prolonged-release melatonin has not. The principal metabolites of melatonin are inactive, similar to the modest residual activity of tasimelteon metabolites. The melatonin formulation is available over the counter in many jurisdictions (as an unregulated supplement), while tasimelteon is a prescription pharmaceutical.

12.3 Agomelatine (Valdoxan)

Mechanism: Dual mechanism: MT1/MT2 melatonin receptor agonist and 5-HT_{2C} serotonin receptor antagonist. The 5-HT_{2C} antagonism contributes noradrenergic and dopaminergic disinhibition in the prefrontal cortex and is the proposed basis for the antidepressant effect [32].

Development trajectory: Developed by Servier and approved by the European Medicines Agency in 2009 for the treatment of major depressive episodes in adults. Not approved by the FDA. Agomelatine is marketed in Europe, Australia, and other jurisdictions as an antidepressant with circadian-resynchronizing properties.

Novelty: Moderate. The dual MT1/MT2 agonist plus 5-HT_{2C} antagonist mechanism is unique among marketed agents and represents a mechanistically differentiated antidepressant approach.

Effect size: Moderate for depression. Meta-analyses report antidepressant efficacy comparable to SSRIs with improved sleep quality measures [32]. For circadian rhythm sleep-wake disorders specifically, agomelatine has not been studied in the Non-24 population and has not produced circadian entrainment data.

Promising potential: Moderate for depression with circadian dysregulation; low for primary circadian rhythm disorders.

Side-effect profile: Less favorable than tasimelteon owing to hepatotoxicity risk. Agomelatine carries a requirement for baseline and periodic liver function test monitoring because of reported cases of clinically significant hepatotoxicity (ALT elevations greater than 10 times the upper limit of normal, rare cases of hepatic failure) [32]. This hepatotoxicity signal is materially worse than the modest transaminase elevation observed with tasimelteon.

Overall validation: Moderate to high for depression; low for circadian rhythm sleep-wake disorders.

Comparison to tasimelteon: Agomelatine and tasimelteon share MT1/MT2 agonism but differ in selectivity profile (agomelatine has the additional 5-HT_{2C} antagonist mechanism), approved indication (depression versus Non-24/SMS), and hepatic safety (agomelatine carries a hepatotoxicity monitoring requirement; tasimelteon does not). Tasimelteon is the superior choice for circadian rhythm disorders; agomelatine is positioned for depression with circadian dysregulation.

12.4 Suvorexant (Belsomra)

Mechanism: Dual orexin receptor antagonist (DORA). Suvorexant blocks both orexin-1 (OX1R) and orexin-2 (OX2R) receptors, inhibiting the wake-promoting orexin signaling system [33]. This mechanism is fundamentally different from melatonin receptor agonism.

Development trajectory: Developed by Merck and approved by the FDA in 2014 for the treatment of insomnia characterized by difficulties with sleep onset and sleep maintenance [33]. Suvorexant represents the first approved orexin receptor antagonist.

Novelty: High. The DORA mechanism is fundamentally distinct from melatonin receptor agonism and represents a genuinely different therapeutic approach to sleep-wake regulation. The mechanism addresses the wake-promoting side of the

sleep-wake equation rather than the circadian-entrainment side.

Effect size: Moderate. Suvorexant demonstrates reductions in sleep onset latency and wake after sleep onset that are larger than those reported for melatonin receptor agonists, consistent with the potent wake-suppressive mechanism [33].

Promising potential: Moderate to high for insomnia. The DORA class has expanded with lemborexant (Dayvigo, 2019) and has an active development pipeline. However, orexin antagonists are not indicated for circadian rhythm sleep-wake disorders and do not produce circadian entrainment.

Side-effect profile: Less favorable than tasimelteon. Suvorexant is a Schedule IV controlled substance owing to abuse potential concerns. Adverse events include somnolence, headache, dizziness, and reports of sleep paralysis, hallucinations, and complex sleep behaviors (sleep-walking, sleep-driving) [33]. Tasimelteon has no abuse potential and no scheduled substance classification.

Overall validation: Moderate to high for insomnia.

Comparison to tasimelteon: Suvorexant and tasimelteon address different aspects of sleep-wake regulation. Suvorexant suppresses wake-promoting orexin signaling; tasimelteon entrains the circadian clock through melatonin receptor agonism. The two mechanisms are complementary rather than competing. Tasimelteon is the choice for circadian rhythm disorders; suvorexant is the choice for insomnia with wake-maintenance difficulty. The combination has not been studied but is pharmacologically rational for patients with both circadian misalignment and insomnia.

12.5 Melatonin (over-the-counter supplement)

Mechanism: Non-selective MT1/MT2 agonist (endogenous ligand). Available over the counter in many jurisdictions (United States, Canada, much of Europe) as a dietary supplement in immediate-release formulations at doses ranging from 0.3 mg to 10 mg or higher [34].

Development trajectory: Melatonin has been studied extensively in academic and clinical settings for insomnia, jet lag, circadian rhythm disorders, and numerous other applications over more than five decades. It is not FDA-approved for any indication but is widely used as a supplement.

Novelty: None. The endogenous ligand has no structural or mechanistic novelty.

Effect size: Variable and dose-dependent. For circadian phase-shifting, exogenous melatonin at physiological replacement doses (0.3 to 0.5 mg) and pharmacological doses (3 to 5 mg) has demonstrated phase-shifting in healthy volunteers and in some circadian disorder populations [34]. However, melatonin has not been evaluated in the rigorous Phase 3 trial design used for tasimelteon in Non-24, and its efficacy for sustained circadian entrainment in totally blind individuals is not established by registration-quality evidence.

Promising potential: Low for regulatory approval; high for continued supplement use. The compound is unlikely to undergo regulatory development given its widespread unregulated availability.

Side-effect profile: Excellent. Melatonin has an extremely favorable safety profile at therapeutic doses, with minimal adverse events and no abuse potential [34]. Quality concerns exist for supplement-grade material (inconsistent dosing, contamination with serotonin or other impurities in some formulations).

Overall validation: Low (by regulatory standards). The clinical research literature on melatonin is vast but heterogeneous in quality, and the compound lacks the regulatory validation that tasimelteon has achieved through Phase 3 trials and FDA approval.

Comparison to tasimelteon: Melatonin and tasimelteon share the target (MT1/MT2 receptors) but differ in pharmacokinetic properties (melatonin has a shorter half-life, lower and more variable bioavailability, and rapid first-pass metabolism), regulatory status (tasimelteon is FDA-approved; melatonin is not), evidence quality (tasimelteon has Phase 3 registration-quality data; melatonin has heterogeneous academic study data), and quality assurance (pharmaceutical-grade tasimelteon versus variable-quality supplement-grade melatonin). For research applications requiring regulatory-grade evidence of circadian entrainment in totally blind individuals, tasimelteon is the validated choice.

12.6 Comparator summary

The five comparators occupy distinct positions in the melatonin receptor agonist and sleep-wake pharmacology landscape. **Ramelteon** is the established melatonin agonist for insomnia but lacks circadian entrainment evidence and has the opposite receptor selectivity profile from tasimelteon. **Prolonged-release melatonin** is

the formulated endogenous ligand with a clean safety profile but limited circadian rhythm data. **Agomelatine** is a mechanistically differentiated antidepressant with melatonergic activity but carries a hepatotoxicity monitoring requirement that limits its applicability to circadian disorders. **Suvorexant** represents a fundamentally different mechanism (orexin antagonism) that is complementary rather than competing with melatonin agonism. **Melatonin** is the endogenous ligand available as an unregulated supplement with extensive but heterogeneous evidence and inconsistent pharmaceutical quality.

Tasimelteon occupies a unique position in this comparator landscape as the only melatonin receptor agonist with regulatory approval for a circadian rhythm sleep-wake disorder. It is the only agent in this panel with Phase 3 evidence of circadian entrainment in totally blind individuals with Non-24, the only agent approved for Smith-Magenis Syndrome sleep disturbances, and the agent with the most favorable MT2-preferring selectivity profile for chronobiotic applications. Its principal limitations relative to the comparators are the short elimination half-life (shorter than ramelteon's active metabolite exposure), the modest bioavailability (38 percent), the hepatic transaminase elevation signal (greater than melatonin or ramelteon), and the higher cost of pharmaceutical-grade material relative to supplement-grade melatonin.

For research applications in circadian rhythm biology, tasimelteon is the reference standard among synthetic melatonin receptor agonists by virtue of its clean receptor selectivity, its MT2-preferring profile, its established regulatory dossier, and the availability of both pharmaceutical-grade and research-grade material from reputable suppliers. The compound is positioned at the intersection of circadian biology, sleep medicine, and rare disease pharmacotherapy.

13. References

1. Vanda Pharmaceuticals, Inc. Tasimelteon (VEC-162) development program documentation. Vanda Pharmaceuticals internal filings and SEC disclosures, 2004-2014.
2. Lockley SW, Dressman MA, Licamele L, et al. Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials. *Lancet*. 2015;386(10005):1754-1764.
3. Vachharajani NN, Yeleswaram K, Boulton DW. Preclinical pharmacokinetics and metabolism of BMS-214778, a novel melatonin receptor agonist. *J Pharm Sci*. 2003;92(4):760-772.
4. Kato K, Hirai K, Nishiyama K, et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. *Neuropharmacology*. 2005;48(2):301-310.
5. Repka LM, Roque JB, Lindsey EE, et al. Synthesis of cyclopropane-containing melatonin receptor agonist analogs. Bristol-Myers Squibb Company patent literature and published synthetic methodology.
6. De Leersnyder H, Zisapel N, Laudon M. Prolonged-release melatonin for children with neurodevelopmental disorders. *Pediatr Neurol*. 2011;45(6):345-349. (For SMS: Vanda Pharmaceuticals FDA approval press release, December 2020; FDA-approved labeling for Hetlioz and Hetlioz LQ, NDA 214517.)
7. Sack RL, Brandes RW, Kendall AR, Lewy AJ. Entrainment of free-running circadian rhythms by melatonin in blind people. *N Engl J Med*. 2000;343(15):1070-1077.
8. Lockley SW, Arendt J, Skene DJ. Visual impairment and circadian rhythm disorders. *Dialogues Clin Neurosci*. 2007;9(3):301-314.
9. Lavedan C, Forber T, Gavin B, et al. Tasimelteon: a selective and unique receptor binding profile. *Neuropharmacology*. 2015;91:259-271.
10. Vanda Pharmaceuticals. Hetlioz (tasimelteon) NDA 205677 pharmacology review. Center for Drug Evaluation and Research. 2014.

11. Torres R, Kramer WG, Baroldi P. Pharmacokinetics of the dual melatonin receptor agonist tasimelteon in subjects with hepatic or renal impairment. *J Clin Pharmacol*. 2015;55(5):525-533.
12. Torres R, Dressman MA, Kramer WG, Baroldi P. Absolute bioavailability of tasimelteon. *J Clin Pharmacol*. 2015;55(Suppl S5):S65.
13. Rajaratnam SM, Polymeropoulos MH, Fisher DM, et al. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials. *Lancet*. 2009;373(9662):482-491.
14. Vanda Pharmaceuticals. Phase III data show Vanda Pharmaceuticals' tasimelteon (VEC-162) significantly improves sleep in patients with chronic insomnia. Press release, June 2008.
15. Hetlioz (tasimelteon) capsules. Full prescribing information. Vanda Pharmaceuticals Inc. Revised 2020.
16. US Food and Drug Administration. Complete Response Letter for Hetlioz sNDA for jet lag disorder. 2019.
17. Vanda Pharmaceuticals. Vanda Pharmaceuticals announces receipt of FDA decision letter on HETLIOZ supplemental new drug application for jet lag disorder. Press release, January 2026.
18. Dubocovich ML, Delagrange P, Krause DN, Sugden D, Cardinali DP, Olcese J. International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors. *Pharmacol Rev*. 2010;62(3):343-380.
19. Liu C, Weaver DR, Jin X, et al. Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. *Neuron*. 1997;19(1):91-102.
20. Torres R, Dressman MA, Kramer WG, Baroldi P. Open-label study to assess the absolute bioavailability of tasimelteon (HETLIOZ). *ClinicalTrials.gov* NCT02130999.
21. Ogilvie BW, Torres R, Dressman MA, Kramer WG, Baroldi P. Clinical assessment of drug-drug interactions of tasimelteon, a novel dual melatonin receptor agonist. *J Clin Pharmacol*. 2015;55(9):1004-1011.

22. Williams WP III, McLin DE III, Dressman MA, Neubauer DN. Comparative review of approved melatonin agonists for the treatment of circadian rhythm sleep-wake disorders. *Pharmacotherapy*. 2016;36(9):1028-1041.
23. Smith ACM, Boyd KE, Brennan GM, et al. Smith-Magenis syndrome. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. *GeneReviews*. University of Washington, Seattle; 2001 (updated 2019).
24. ClinicalTrials.gov. Tasimelteon for autism and sleep disorders. NCT identifier (Phase 3, recruiting as of 2021).
25. Sigma-Aldrich/MilliporeSigma. Tasimelteon, catalog number SML2030. Product specification sheet.
26. Selleck Chemicals. Tasimelteon (BMS-214778, VEC-162), catalog number S8025. Product datasheet.
27. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases. Tasimelteon. Updated 2020.
28. Owen RT. Ramelteon: profile of a new sleep-promoting medication. *Drugs Today (Barc)*. 2006;42(4):255-263.
29. Kuriyama A, Honda M, Hayashino Y. Ramelteon for the treatment of insomnia in adults: a systematic review and meta-analysis. *Sleep Med*. 2014;15(4):385-392.
30. Karim A, Tolbert D, Cao C. Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. *J Clin Pharmacol*. 2006;46(2):140-148.
31. Lemoine P, Nir T, Laudon M, Zisapel N. Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. *J Sleep Res*. 2007;16(4):372-380.
32. Taylor D, Sparshatt A, Varma S, Olofinjana O. Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies. *BMJ*. 2014;348:g1888.
33. Herring WJ, Connor KM, Ivgy-May N, et al. Suvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trials. *Biol Psychiatry*. 2016;79(2):136-148.

34. Costello RB, Lentino CV, Boyd CC, et al. The effectiveness of melatonin for promoting healthy sleep: a rapid evidence assessment of the literature. *Nutr J.* 2014;13:106.
-

This monograph is provided for research use only. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. Compound class generalizations are noted where compound-specific data are sparse; investigators should weight the evidence accordingly. Tasimelteon is approved by the United States Food and Drug Administration for the treatment of Non-24-Hour Sleep-Wake Disorder in totally blind individuals (Hetlioz, 2014) and for the treatment of nighttime sleep disturbances associated with Smith-Magenis Syndrome (Hetlioz/Hetlioz LQ, 2020). Investigators should consult their local regulatory authority and the current prescribing information before any human research application.